Educational intervention on treatment choices for prostate cancer patients on hormone therapy
A Feasibility Study of Orchiectomy in Patients With Prostate Cancer on Chronic LHRH Agonist or Antagonist Therapy
This study tests if giving information about surgery as an option can help men with advanced prostate cancer who are on hormone therapy feel more open to considering it as a treatment choice.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT04705038 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate how providing education about orchiectomy as an alternative to ongoing medical castration influences the willingness of patients with metastatic prostate cancer to consider this surgical option. Patients who have been on hormone therapy for at least one year will receive information and resources to help them make informed decisions regarding their treatment. The study will assess changes in treatment preferences following the educational intervention.
Who should consider this trial
Good fit: Ideal candidates are men diagnosed with metastatic prostatic adenocarcinoma who have been on hormone therapy for at least one year.
Not a fit: Patients who have undergone more than two prior systemic treatment regimens or are not fluent in English may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could empower patients with prostate cancer to make more informed treatment decisions, potentially improving their quality of life.
How similar studies have performed: While educational interventions in cancer treatment decision-making have shown promise in other contexts, this specific approach regarding orchiectomy in prostate cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of metastatic prostatic adenocarcinoma * Receiving luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist therapy continuously for at least 1 year with anticipated lifelong therapy * Able to complete written surveys in English Exclusion Criteria: * More than 2 prior systemic treatment regimens utilized in addition to castration.
Where this trial is running
Chicago, Illinois
- University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Personalized Cancer Care Consortium
- Email: PhaseIICRA@medicine.bsd.uchicago.edu
- Phone: 773.702.1220
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.